WO2018065924A1 - Intermediates of mitogen-activated protein kinase kinase (map2k or mek) inhibitors and process for their preparation - Google Patents

Intermediates of mitogen-activated protein kinase kinase (map2k or mek) inhibitors and process for their preparation Download PDF

Info

Publication number
WO2018065924A1
WO2018065924A1 PCT/IB2017/056133 IB2017056133W WO2018065924A1 WO 2018065924 A1 WO2018065924 A1 WO 2018065924A1 IB 2017056133 W IB2017056133 W IB 2017056133W WO 2018065924 A1 WO2018065924 A1 WO 2018065924A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
bromo
formula
fluoro
methyl
Prior art date
Application number
PCT/IB2017/056133
Other languages
French (fr)
Inventor
Anil SAINI
Muddassar Ajij KAZI
Mahavir Singh Khanna
Mohan Prasad
Original Assignee
Sun Pharmaceutical Industries Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Limited filed Critical Sun Pharmaceutical Industries Limited
Publication of WO2018065924A1 publication Critical patent/WO2018065924A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2

Definitions

  • the present invention relates to intermediates of Mitogen-activated protein kinase kinase (MAP2K or MEK) inhibitors such as Selumetinib, Binimetinib and process for their preparation.
  • MEK Mitogen-activated protein kinase kinase
  • the present invention also relates to the process for the preparation of MEK inhibitors such as Selumetinib and Binimetinib.
  • Selumetinib of Formula A is chemically known as 5-[(4-Bromo-2- chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-l-methyl-lH-benzimidazole-6- carboxamide.
  • Selumetinib is under clinical trials for various types of cancer such as KRAS- mutant advanced or metastatic non-small cell lung cancer, differentiated thyroid cancer, neurofibromatosis Type 1.
  • Binimetinib of Formula B is chemically known as 5-[(4-Bromo-2- fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-l-methyl-lH-benzimidazole-6- carboxamide.
  • Binimetinib is under clinical trials for various types of cancer such as BRAF- mutant melanoma and NRAS-mutant melanoma.
  • PCT Publication No. WO 03/077914 provides a process for the preparation of methyl 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-l-methyl-lH-benzimidazole-6- carboxylate (Formula 1, when R 1 is (4-bromo-2-chlorophenyl)amino, R 2 is methoxy).
  • the process involves i) cyclization of 4,5-Diamino-2-(2-chloro-phenylamino)-3-fluoro-benzoic acid methyl ester with formamidine acetate to obtain Methyl 5-[(2-chlorophenyl)amino]-4- fluoro-lH-benzimidazole-6-carboxylate, ii) bromination of Methyl 5-[(2- chlorophenyl)amino]-4-fluoro- lH-benzimidazole-6-carboxylate with N- bromosuccinamide to obtain Methyl 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-lH- benzimidazole-6-carboxylate, and iii) reacting Methyl 5-[(4-bromo-2- chlorophenyl)amino]-4-fluoro-lH-benzimidazole-6-carboxylate with iodome
  • PCT Publication No. WO 2007/002157 provides a process for the preparation of Methyl 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-l-methyl-lH-benzimidazole-6- carboxylate (Formula 1, when R 1 is (4-bromo-2-chlorophenyl)amino, R 2 is methoxy).
  • the process involves i) reduction of Methyl 2,4-diamino-3-fluoro-5-nitrobenzoate using Palladium/Carbon to obtain Methyl 2,4,5 -triamino-3-fluorobenzoate which is in-situ reacted with diethoxymethane in the presence of >-toluene sulfonic acid to obtain 6- Amino-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid methyl ester, and ii) reacting 6-Amino-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid methyl ester with bromochloroiodobenzene using Palladium acetate/Xantphos/Cesium carbonate to obtain Methyl 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-l-methyl-lH-benzimidazole- 6-carboxylate in 66% yield
  • PCT Publication Nos. WO 2007/076245 and WO 2009/036020 provide a process for the preparation of Methyl 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-l-methyl-lH- benzimidazole-6-carboxylate (Formula 1, when R 1 is (4-bromo-2-chlorophenyl) amino, R 2 is methoxy).
  • the process involves i) cyclization of 4-Amino-3-fluoro-5-nitro-2- (phenylamino)-benzoic acid methyl ester using formic acid/palladium hydroxide/carbon to obtain Methyl 4-fluoro-5-(phenylamino)-lH-benzimidazole-6-carboxylate, ii) bromination of Methyl 4-fluoro-5-(phenylamino)-lH-benzimidazole-6-carboxylate with N- bromosuccinamide to obtain Methyl 5-[(4-bromophenyl)amino]-4-fluoro-lH- benzimidazole-6-carboxylate, and iii) chlorination of Methyl 5-[(4-bromophenyl)amino]- 4-fluoro-lH-benzimidazole-6-carboxylate with N-chlorosuccinamide to obtain Methyl 5- [(4-bromo-2
  • PCT Publication No. WO 2013/0142182 provides a process for the preparation of 6-(4-Bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid methyl ester (Formula 1, wherein R 1 is (4-bromo-2-fluorophenyl)amino, R 2 is methoxy).
  • the process involves i) converting 4-Amino-3-fluoro-2-(2-fluoro- phenylamino)-5-nitro-benzoic acid methyl ester by reduction/cyclization and bromination to obtain 6-(4-Bromo-2-fluorophenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylic acid methyl ester, and ii) treating 6-(4-Bromo-2-fluoro-phenylamino)-7-fluoro-3H- benzoimidazole-5-carboxylic acid methyl ester with iodomethane in the presence of potassium carbonate in dimethylformamide followed by flash chromatography to isolate 6-(4-Bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid methyl ester.
  • the present invention provides a compound of Formula 1, which is a useful intermediate for the preparation of MEK inhibitors such as Selumetinib and Binimetinib.
  • R 1 is independently selected from the group consisting of fluoro, chloro, bromo, phenylamino, or (4-bromophenyl)amino; and R 2 is independently selected from the group consisting of hydroxy, Ci-C6 alkoxy, 0-(2-vinyloxy-ethyl)-hydroxylamino, or O- (hydroxyethyl)-hydroxylamino .
  • R 1 is independently selected from the group consisting of fluoro, chloro, bromo, phenylamino, (4-bromophenyl)amino, (4-bromo-2-chlorophenyl) amino, or (4-bromo-2- fluorophenyl) amino; and R 2 is independently selected from the group consisting of hydroxy, C1-C6 alkoxy, 0-(2-vinyloxy-ethyl)-hydroxylamino, or O-(hydroxyethyl)- hydroxylamino.
  • the present invention provides an efficient and an industrially feasible process for the preparation of compounds of Formula 1 in a good yield and an excellent chemical purity with a reduced number of process steps.
  • the present invention avoids the excess use of environmentally hazardous/costly reagent(s).
  • solvent refers to any solvent or solvent mixtures, including, for example, water, aromatic hydrocarbons, esters, halogenated
  • hydrocarbons examples include toluene and xylene.
  • aromatic hydrocarbons examples include toluene and xylene.
  • esters examples include ethyl acetate, ⁇ -propyl acetate, isopropyl acetate, and «-butyl acetate.
  • halogenated hydrocarbons include dichloromethane, chloroform, and 1,2- dichloroethane.
  • ketones include acetone and methyl ethyl ketone.
  • ethers include diethyl ether and tetrahydrofuran.
  • polar aprotic solvents include NN-dimethylformamide, NN-dimethylacetamide,
  • C1-C6 alkoxy refers to a linear or a branched chain alkoxy group having C1-C6 carbon atoms which include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, and fert-butoxy.
  • C1-C6 dialkoxy refers to a linear or a branched chain dialkoxy group having C1-C6 carbon atoms which include, but are not limited to, dimethoxy, diethoxy, dipropoxy, diisopropoxy, dibutoxy, disec-butoxy, and ditert- butoxy.
  • a first aspect of the present invention provides a compound of Formula 1,
  • R 1 is independently selected from the group consisting of fluoro, chloro, bromo, phenylamino, or (4-bromophenyl)amino; and R 2 is independently selected from the group consisting of hydroxy, C1-C6 alkoxy, 0-(2-vinyloxy-ethyl)-hydroxylamino, or O- (hydroxyethyl)-hydroxylamino .
  • the compound of Formula 1 is a suitable intermediate for the preparation of
  • a second aspect of the present invention provides a process for the preparation of compound of Formula 1,
  • R 1 is independently selected from the group consisting of fluoro, chloro, bromo, phenylamino, (4-bromophenyl)amino, (4-bromo-2-chlorophenyl)amino, or (4-bromo-2- fluorophenyl)amino; and R 2 is independently selected from the group consisting of hydroxy, C1-C6 alkoxy, 0-(2-vinyloxy-ethyl)-hydroxylamino, or O-(hydroxyethyl)- hydroxylamino comprising treating a compound of Formula 2 or a salt thereof,
  • R 1 and R 2 are as defined above, with C1-C6 dialkoxymethane in the presence of an acid.
  • the compound of Formula 2 may be prepared by any methods known in the art, for example, the method described in PCT Publication No. WO 03/077914 or as described herein.
  • the treatment of the compound of Formula 2 or a salt thereof with C1-C6 dialkoxymethane includes adding, slurrying, dissolving, stirring, or a combination thereof in the presence of a suitable solvent at a temperature of about 25°C to reflux temperature for a time period sufficient to complete the reaction.
  • Suitable C1-C6 dialkoxymethane is diethoxymethane or dimethoxymethane.
  • Suitable acid is selected from the group consisting of an inorganic acid or an organic acid.
  • inorganic acid include hydrochloric acid and sulfuric acid.
  • organic acid include sulfonic acid derivatives or carboxylic acids.
  • sulfonic acid derivatives include methane sulfonic acid, / toluene sulfonic acid, and benzene sulfonic acid.
  • carboxylic acids include formic acid and acetic acid.
  • the compound of Formula 1 may optionally be isolated by cooling,
  • the isolated compound of Formula 1 may be purified by treating with suitable solvent(s) at a temperature of about 25 °C to reflux temperature.
  • suitable solvent(s) includes adding, slurrying, dissolving, stirring, or a combination thereof.
  • the compound of Formula 1 when R 1 is not (4-bromo-2-fluorophenyl)amino and/or R 2 is not 0-(hydroxyethyl)-hydroxylamino can be converted to Binimetinib by any methods known in the art, for example, the method described in PCT Publication Nos. WO 03/077914, WO 2013/142182, and WO 2014063024.
  • Aqueous sodium hydroxide solution (10%, 140 mL) was added to the reaction mixture and then stirred for 30 minutes.
  • the solid obtained was filtered under vacuum and washed with deionized water (2 x 70 mL).
  • Methanol (84 mL) was added to the wet solid and the reaction mixture was heated to 45 °C to 50°C.
  • Water (56 mL) was added over a period of 10 minutes, and the reaction mixture was stirred for 10 minutes at 45°C to 50°C and then cooled to 20°C to 25°C.
  • the reaction mixture was stirred for 30 minutes at 20°C to 25 °C.
  • the solid obtained was filtered under vacuum and washed with a mixture of methanol: deionized water (28 mL, 1 : 1 ratio).
  • the wet material was dried under vacuum at 35°C to 40°C for 14 hours to obtain the title compound.
  • N-Bromosuccinamide (8.04 g) was added to a solution of Methyl 4-fluoro-l- methyl-5-(phenylamino)-lH-benzimidazole-6-carboxylate (10 g; obtained from Example 2) in dimethylformamide (400 mL) at 15°C to 20°C over a period of 10 minutes.
  • the reaction mixture was stirred for 1 hour at 15°C to 20°C. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to 10°C to 15°C.
  • a solution of sodium bisulfite (6.9 g) in deionized water (1600 mL) was added and then stirred for 30 minutes.
  • the solid obtained was filtered under vacuum and then washed with deionized water (2 x 100 mL).
  • Methanol (100 mL) was added to the wet solid and the reaction mixture was heated to 45 °C to 50°C.
  • Water (100 mL) was added over a period of 10 minutes and the reaction mixture was stirred for 10 minutes at 45°C to 50°C and then cooled to 20°C to 25°C.
  • the reaction mixture was stirred for 30 minutes at 20°C to 25°C.
  • the solid obtained was filtered under vacuum and then washed with a mixture of methanol and deionized water (20 mL, 1 : 1 ratio).
  • the wet solid was dried under vacuum at 35°C to 40°C for 14 hours to obtain the title compound.
  • N-Chlorosuccinimide (3.64 g) was added to a solution of Methyl 5-[(4- bromophenyl)amino]-4-fluoro-l -methyl- lH-benzimidazole-6-carboxy late (10 g; obtained from Example 3) in dimethylformamide (300 mL) at 15°C to 20°C.
  • the reaction mixture was stirred for 42 hours at 15°C to 20°C.
  • a solution of sodium bisulfite (5.5 g in deionized water (2100 mL)) was added and stirred for 15 minutes at 20°C to 25°C.
  • the solid obtained was filtered under vacuum and washed with deionized water (2 x 30 mL). Methyl fert-butyl ether (100 mL) was added to the wet solid and the reaction mixture was heated to 45 °C to 50°C, stirred for 15 minutes and then cooled to 20°C to 25°C. The reaction mixture was stirred for 30 minutes at 20°C to 25 °C. The solid obtained was filtered under vacuum, washed with methyl fert-butyl ether (10 mL), and then dried under vacuum at 35°C to 40°C for 14 hours to obtain the title compound.
  • Deionized water (10 mL) was added to a solution of Methyl-5-[(4-bromo-2- chlorophenyl)-amino]-4-fluoro-l-methyl-lH-benzimidazole-6-carboxylate (2 g; obtained from Example 4) in tetrahydrofuran (20 mL) and the temperature was maintained at 25 °C to 30°C.
  • a solution of sodium hydroxide (0.74 g) in deionized water (4 mL) was added gradually to the reaction mixture at 25°C to 30°C over a period of 10 minutes. The reaction mixture was stirred for 3 hours at 25 °C to 30°C.
  • Aqueous hydrochloric acid (IN, 1.2 mL hydrochloric acid in 12 mL deionized water) was added slowly to a solution of 5-[(4-Bromo-2-chlorophenyl)amino]-N-[2- (ethenyloxy)ethoxy]-4-fluoro-l -methyl- lH-benzimidazole-6-carboxamide (1.3 g; obtained from Example 6) in ethanol (30 mL) over a period of 10 minutes and the reaction mixture was stirred at 25 °C to 30°C for 24 hours. After completion of the reaction (monitored by TLC), ethanol was concentrated under vacuum.

Abstract

The present invention relates to intermediates of Mitogen-activated protein kinase kinase (MAP2K or MEK) inhibitors such as Selumetinib, Binimetinib and process for their preparation. The present invention also relates to process for the 5 preparation of MEK inhibitors such as Selumetinib, and Binimetinib.

Description

INTERMEDIATES OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MAP2K OR MEK) INHIBITORS AND PROCESS FOR THEIR PREPARATION
Field of the Invention
The present invention relates to intermediates of Mitogen-activated protein kinase kinase (MAP2K or MEK) inhibitors such as Selumetinib, Binimetinib and process for their preparation. The present invention also relates to the process for the preparation of MEK inhibitors such as Selumetinib and Binimetinib.
Background of the Invention
Selumetinib of Formula A, is chemically known as 5-[(4-Bromo-2- chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-l-methyl-lH-benzimidazole-6- carboxamide.
Figure imgf000002_0001
Formula A
Selumetinib is under clinical trials for various types of cancer such as KRAS- mutant advanced or metastatic non-small cell lung cancer, differentiated thyroid cancer, neurofibromatosis Type 1.
Binimetinib of Formula B, is chemically known as 5-[(4-Bromo-2- fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-l-methyl-lH-benzimidazole-6- carboxamide.
Figure imgf000003_0001
Formula B
Binimetinib is under clinical trials for various types of cancer such as BRAF- mutant melanoma and NRAS-mutant melanoma.
PCT Publication No. WO 03/077914 provides a process for the preparation of methyl 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-l-methyl-lH-benzimidazole-6- carboxylate (Formula 1, when R1 is (4-bromo-2-chlorophenyl)amino, R2 is methoxy). The process involves i) cyclization of 4,5-Diamino-2-(2-chloro-phenylamino)-3-fluoro-benzoic acid methyl ester with formamidine acetate to obtain Methyl 5-[(2-chlorophenyl)amino]-4- fluoro-lH-benzimidazole-6-carboxylate, ii) bromination of Methyl 5-[(2- chlorophenyl)amino]-4-fluoro- lH-benzimidazole-6-carboxylate with N- bromosuccinamide to obtain Methyl 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-lH- benzimidazole-6-carboxylate, and iii) reacting Methyl 5-[(4-bromo-2- chlorophenyl)amino]-4-fluoro-lH-benzimidazole-6-carboxylate with iodomethane in the presence of potassium carbonate in dimethylformamide followed by flash chromatography to isolate Methyl 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-l-methyl-lH- benzimidazole-6-carboxylate in 36% yield.
PCT Publication No. WO 2007/002157 provides a process for the preparation of Methyl 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-l-methyl-lH-benzimidazole-6- carboxylate (Formula 1, when R1 is (4-bromo-2-chlorophenyl)amino, R2 is methoxy). The process involves i) reduction of Methyl 2,4-diamino-3-fluoro-5-nitrobenzoate using Palladium/Carbon to obtain Methyl 2,4,5 -triamino-3-fluorobenzoate which is in-situ reacted with diethoxymethane in the presence of >-toluene sulfonic acid to obtain 6- Amino-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid methyl ester, and ii) reacting 6-Amino-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid methyl ester with bromochloroiodobenzene using Palladium acetate/Xantphos/Cesium carbonate to obtain Methyl 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-l-methyl-lH-benzimidazole- 6-carboxylate in 66% yield.
PCT Publication Nos. WO 2007/076245 and WO 2009/036020 provide a process for the preparation of Methyl 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-l-methyl-lH- benzimidazole-6-carboxylate (Formula 1, when R1 is (4-bromo-2-chlorophenyl) amino, R2 is methoxy). The process involves i) cyclization of 4-Amino-3-fluoro-5-nitro-2- (phenylamino)-benzoic acid methyl ester using formic acid/palladium hydroxide/carbon to obtain Methyl 4-fluoro-5-(phenylamino)-lH-benzimidazole-6-carboxylate, ii) bromination of Methyl 4-fluoro-5-(phenylamino)-lH-benzimidazole-6-carboxylate with N- bromosuccinamide to obtain Methyl 5-[(4-bromophenyl)amino]-4-fluoro-lH- benzimidazole-6-carboxylate, and iii) chlorination of Methyl 5-[(4-bromophenyl)amino]- 4-fluoro-lH-benzimidazole-6-carboxylate with N-chlorosuccinamide to obtain Methyl 5- [(4-bromo-2-chlorophenyl)amino] -4-fluoro- lH-benzimidazole-6-carboxylate, and iv) treating Methyl 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-lH-benzimidazole-6- carboxylate with iodomethane in the presence of potassium carbonate in
dimethylformamide followed by flash chromatography to isolate Methyl 5-[(4-bromo-2- chlorophenyl)amino]-4-fluoro-l-methyl-lH-benzimidazole-6-carboxylate in 36% yield.
PCT Publication No. WO 2013/0142182 provides a process for the preparation of 6-(4-Bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid methyl ester (Formula 1, wherein R1 is (4-bromo-2-fluorophenyl)amino, R2 is methoxy). The process involves i) converting 4-Amino-3-fluoro-2-(2-fluoro- phenylamino)-5-nitro-benzoic acid methyl ester by reduction/cyclization and bromination to obtain 6-(4-Bromo-2-fluorophenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylic acid methyl ester, and ii) treating 6-(4-Bromo-2-fluoro-phenylamino)-7-fluoro-3H- benzoimidazole-5-carboxylic acid methyl ester with iodomethane in the presence of potassium carbonate in dimethylformamide followed by flash chromatography to isolate 6-(4-Bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid methyl ester.
PCT Publication Nos. WO 03/077914 and WO 2007/076245 provide processes for the preparation of Selumetinib.
PCT Publication Nos. WO 03/077914, WO 2013/142182, and WO 2014063024 provide processes for the preparation of Binimetinib. The processes described in the prior arts for the preparation of compounds of Formula 1 (when R1 is (4-bromo-2-chlorophenyl)amino, (4-bromo-2-fluorophenyl)amino, R2 is methoxy) suffers from one or more of the disadvantages such as low yield, increased number of chemical reaction steps, difficulties in isolation of the products, flash chromatography, and use of hazardous and costly reagents such as Xanthphos.
Thus, there is a need in the art to develop a new process for the preparation of compounds of Formula 1 which is efficient and commercially feasible.
Summary of the Invention
The present invention provides a compound of Formula 1, which is a useful intermediate for the preparation of MEK inhibitors such as Selumetinib and Binimetinib.
Figure imgf000005_0001
Formula 1
wherein R1 is independently selected from the group consisting of fluoro, chloro, bromo, phenylamino, or (4-bromophenyl)amino; and R2 is independently selected from the group consisting of hydroxy, Ci-C6 alkoxy, 0-(2-vinyloxy-ethyl)-hydroxylamino, or O- (hydroxyethyl)-hydroxylamino .
The present inventors have also developed an improved process for the preparation of compound of Formula 1,
Figure imgf000005_0002
wherein R1 is independently selected from the group consisting of fluoro, chloro, bromo, phenylamino, (4-bromophenyl)amino, (4-bromo-2-chlorophenyl) amino, or (4-bromo-2- fluorophenyl) amino; and R2 is independently selected from the group consisting of hydroxy, C1-C6 alkoxy, 0-(2-vinyloxy-ethyl)-hydroxylamino, or O-(hydroxyethyl)- hydroxylamino.
The present invention provides an efficient and an industrially feasible process for the preparation of compounds of Formula 1 in a good yield and an excellent chemical purity with a reduced number of process steps. The present invention avoids the excess use of environmentally hazardous/costly reagent(s).
Detailed Description of the Invention
The term "solvent," as used herein, refers to any solvent or solvent mixtures, including, for example, water, aromatic hydrocarbons, esters, halogenated
hydrocarbons, ketones, ethers, polar aprotic solvents, or mixtures thereof. Examples of aromatic hydrocarbons include toluene and xylene. Examples of esters include ethyl acetate, ^-propyl acetate, isopropyl acetate, and «-butyl acetate. Examples of halogenated hydrocarbons include dichloromethane, chloroform, and 1,2- dichloroethane. Examples of ketones include acetone and methyl ethyl ketone.
Examples of ethers include diethyl ether and tetrahydrofuran. Examples of polar aprotic solvents include NN-dimethylformamide, NN-dimethylacetamide,
dimethylsulphoxide, acetonitrile, and N-methylpyrrolidone.
The term "C1-C6 alkoxy," as used herein, refers to a linear or a branched chain alkoxy group having C1-C6 carbon atoms which include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, and fert-butoxy.
The term "C1-C6 dialkoxy," as used herein, refers to a linear or a branched chain dialkoxy group having C1-C6 carbon atoms which include, but are not limited to, dimethoxy, diethoxy, dipropoxy, diisopropoxy, dibutoxy, disec-butoxy, and ditert- butoxy.
A first aspect of the present invention provides a compound of Formula 1,
Figure imgf000006_0001
Formula 1 wherein R1 is independently selected from the group consisting of fluoro, chloro, bromo, phenylamino, or (4-bromophenyl)amino; and R2 is independently selected from the group consisting of hydroxy, C1-C6 alkoxy, 0-(2-vinyloxy-ethyl)-hydroxylamino, or O- (hydroxyethyl)-hydroxylamino .
The compound of Formula 1 is a suitable intermediate for the preparation of
Selumetinib and Binimetinib.
A second aspect of the present invention provides a process for the preparation of compound of Formula 1,
Figure imgf000007_0001
Formula 1
wherein R1 is independently selected from the group consisting of fluoro, chloro, bromo, phenylamino, (4-bromophenyl)amino, (4-bromo-2-chlorophenyl)amino, or (4-bromo-2- fluorophenyl)amino; and R2 is independently selected from the group consisting of hydroxy, C1-C6 alkoxy, 0-(2-vinyloxy-ethyl)-hydroxylamino, or O-(hydroxyethyl)- hydroxylamino comprising treating a compound of Formula 2 or a salt thereof,
Figure imgf000007_0002
Formula 2
wherein R1 and R2 are as defined above, with C1-C6 dialkoxymethane in the presence of an acid.
The compound of Formula 2 may be prepared by any methods known in the art, for example, the method described in PCT Publication No. WO 03/077914 or as described herein. The treatment of the compound of Formula 2 or a salt thereof with C1-C6 dialkoxymethane includes adding, slurrying, dissolving, stirring, or a combination thereof in the presence of a suitable solvent at a temperature of about 25°C to reflux temperature for a time period sufficient to complete the reaction.
Suitable C1-C6 dialkoxymethane is diethoxymethane or dimethoxymethane.
Suitable acid is selected from the group consisting of an inorganic acid or an organic acid. Examples of inorganic acid include hydrochloric acid and sulfuric acid. Examples of organic acid include sulfonic acid derivatives or carboxylic acids.
Examples of sulfonic acid derivatives include methane sulfonic acid, / toluene sulfonic acid, and benzene sulfonic acid. Examples of carboxylic acids include formic acid and acetic acid.
The compound of Formula 1 may optionally be isolated by cooling,
evaporation under vacuum, extraction, washing, crystallization, precipitation, filtration, filtration under vacuum, decantation, centrifugation, drying, or combinations thereof.
The isolated compound of Formula 1 may be purified by treating with suitable solvent(s) at a temperature of about 25 °C to reflux temperature. The treatment of the compound of Formula 1 with a suitable solvent includes adding, slurrying, dissolving, stirring, or a combination thereof.
The compound of Formula 1 when R1 is not (4-bromo-2-chlorophenyl)amino and/or R2 is not 0-(hydroxyethyl)-hydroxylamino can be further converted to
Selumetinib by any methods known in the art, for example, the method described in PCT Publication Nos. WO 03/077914 and WO 2007/076245.
The compound of Formula 1 when R1 is not (4-bromo-2-fluorophenyl)amino and/or R2 is not 0-(hydroxyethyl)-hydroxylamino can be converted to Binimetinib by any methods known in the art, for example, the method described in PCT Publication Nos. WO 03/077914, WO 2013/142182, and WO 2014063024.
While the present invention has been described in terms of its specific aspects and embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
Methods: The NMR spectrum was recorded using Bruker® (Maker), Ultrashield-400 MHz (Model).
The mass spectrum was recorded using ABSCIEX® (Maker), API-2000 (Model).
The following examples are for illustrative purposes only and should not be construed as limiting the scope of the invention in any way.
EXAMPLES
Example 1 : Preparation of Methyl 4.5-diamino-3-fluoro-2-(phenylamino)benzoate p- toluene sulfonate (salt of Formula 2)
Dry Palladium/Carbon (2.5%, 1.4 g) was added to a solution of Methyl 4-amino-3- fluoro-5-nitro-2-(phenylamino)benzoate (14 g) in methanol (70 mL) and tetrahydrofuran (140 mL) while maintaining the temperature at 30°C to 32°C. The reaction mixture was hydrogenated at 3.5 kg to 4.0 kg/cm2 hydrogen pressure for 5 hours at 30°C to 35°C. After completion of the reaction (monitored by Thin Layer Chromatography (TLC)), the reaction mixture was filtered through Hyflo® and washed with methanol (2 x 35 mL). The solvent was recovered under vacuum at 40°C to 45 °C to obtain a residue. Acetonitrile (140 mL) was added to the above residue followed by slow addition of a solution of p- toluene sulfonic acid monohydrate (10.4 g) in acetonitrile (56 mL) at 10°C to 20°C over a period of 15 minutes. The reaction mixture was then stirred for 30 minutes at 10°C to 20°C. The solid obtained was filtered under vacuum and washed with acetonitrile (2 x 35 mL). The wet material obtained was used as such in the next step.
Example 2: Preparation of Methyl 4-fluoro- l-methyl-5-(phenylamino)-lH-benzimidazole- 6-carboxylate (Formula 1)
>-Toluene sulfonic acid monohydrate (1.74 g) was added to a solution of Methyl
4,5-diamino-3-fluoro-2-(phenylamino)benzoate, /J>-toluene sulfonate (obtained from Example 1) in acetonitrile (210 mL) at 20°C to 25 °C. The reaction mixture was heated to 60°C to 65°C. A solution of diethoxymethane (9.55 g) in acetonitrile (14 mL) was added at 60°C to 65 °C over a period of 15 minutes. The reaction mixture was stirred for 2 hours at 60°C to 65°C. After completion of the reaction (monitored by TLC), the solvent was recovered under vacuum and cooled to 20°C to 25 °C. Aqueous sodium hydroxide solution (10%, 140 mL) was added to the reaction mixture and then stirred for 30 minutes. The solid obtained was filtered under vacuum and washed with deionized water (2 x 70 mL). Methanol (84 mL) was added to the wet solid and the reaction mixture was heated to 45 °C to 50°C. Water (56 mL) was added over a period of 10 minutes, and the reaction mixture was stirred for 10 minutes at 45°C to 50°C and then cooled to 20°C to 25°C. The reaction mixture was stirred for 30 minutes at 20°C to 25 °C. The solid obtained was filtered under vacuum and washed with a mixture of methanol: deionized water (28 mL, 1 : 1 ratio). The wet material was dried under vacuum at 35°C to 40°C for 14 hours to obtain the title compound.
Yield: 77.5%
¾ NMR (de-DMSO, 400 MHz): δ 3.78 (s, 3H), 3.89 (s, 3H), 6.64-6.67 (m, 2H), 6.67-6.68 (m, 1H), 7.12-7.16 (m, 2H), 7.96-7.99 (d, 2H), 8.39 (s, 1H).
Mass (m/z): 300.2 [m+l]+
Example 3: Preparation of Methyl 5-r(4-bromophenyl)aminol-4-fluoro-l-methyl-lH- benzimidazole-6-carboxylate
N-Bromosuccinamide (8.04 g) was added to a solution of Methyl 4-fluoro-l- methyl-5-(phenylamino)-lH-benzimidazole-6-carboxylate (10 g; obtained from Example 2) in dimethylformamide (400 mL) at 15°C to 20°C over a period of 10 minutes. The reaction mixture was stirred for 1 hour at 15°C to 20°C. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to 10°C to 15°C. A solution of sodium bisulfite (6.9 g) in deionized water (1600 mL) was added and then stirred for 30 minutes. The solid obtained was filtered under vacuum and then washed with deionized water (2 x 100 mL). Methanol (100 mL) was added to the wet solid and the reaction mixture was heated to 45 °C to 50°C. Water (100 mL) was added over a period of 10 minutes and the reaction mixture was stirred for 10 minutes at 45°C to 50°C and then cooled to 20°C to 25°C. The reaction mixture was stirred for 30 minutes at 20°C to 25°C. The solid obtained was filtered under vacuum and then washed with a mixture of methanol and deionized water (20 mL, 1 : 1 ratio). The wet solid was dried under vacuum at 35°C to 40°C for 14 hours to obtain the title compound.
Yield: 81.7% ¾ NMR (de-DMSO, 400 MHz): δ 3.79 (s, 3H), 3.99 (s, 3H), 6.61-6.63 (m, 2H), 7.26-7.28 (m, 2H), 7.99-8.02 (d, 2H), 8.41 (s, 1H).
Mass (m/z): 378.2, 380.1 [m, m+2]+
Example 4: Preparation of Methyl 5-[(4-bromo-2-chlorophenynamino]-4-fluoro-l-methyl- lH-benzimidazole-6-carboxylate
N-Chlorosuccinimide (3.64 g) was added to a solution of Methyl 5-[(4- bromophenyl)amino]-4-fluoro-l -methyl- lH-benzimidazole-6-carboxy late (10 g; obtained from Example 3) in dimethylformamide (300 mL) at 15°C to 20°C. The reaction mixture was stirred for 42 hours at 15°C to 20°C. After completion of the reaction (monitored by TLC), a solution of sodium bisulfite (5.5 g in deionized water (2100 mL)) was added and stirred for 15 minutes at 20°C to 25°C. The solid obtained was filtered under vacuum and washed with deionized water (2 x 30 mL). Methyl fert-butyl ether (100 mL) was added to the wet solid and the reaction mixture was heated to 45 °C to 50°C, stirred for 15 minutes and then cooled to 20°C to 25°C. The reaction mixture was stirred for 30 minutes at 20°C to 25 °C. The solid obtained was filtered under vacuum, washed with methyl fert-butyl ether (10 mL), and then dried under vacuum at 35°C to 40°C for 14 hours to obtain the title compound.
Yield: 76.1%
¾ NMR (de-DMSO, 400 MHz): δ 3.83 (s, 3H), 3.93 (s, 3H), 6.42-6.45 (m, 1H), 7.27-7.30 (m, 1H), 7.63-7.64 (d, 1H), 8.10 (s, 1H), 8.14 (s, 1H), 8.46 (s, 1H).
Mass (m/z): 412.1, 414.1 [m, m+2]+
Example 5: Preparation of 5-r(4-Bromo-2-chlorophenyl)aminol-4-fluoro-l-methyl-lH- benzimidazole-6-carboxylic acid
Deionized water (10 mL) was added to a solution of Methyl-5-[(4-bromo-2- chlorophenyl)-amino]-4-fluoro-l-methyl-lH-benzimidazole-6-carboxylate (2 g; obtained from Example 4) in tetrahydrofuran (20 mL) and the temperature was maintained at 25 °C to 30°C. A solution of sodium hydroxide (0.74 g) in deionized water (4 mL) was added gradually to the reaction mixture at 25°C to 30°C over a period of 10 minutes. The reaction mixture was stirred for 3 hours at 25 °C to 30°C. After completion of the reaction (monitored by TLC), tetrahydroiuran was recovered under vacuum at 40°C to 45°C and deionized water (20 mL) was added . The aqueous reaction mixture was washed with dichloromethane (2 x 20 mL). The reaction mixture was cooled to 5°C to 10°C and the pH of aqueous layer was adjusted to 1.3 with 50% aqueous hydrochloric acid solution and then stirred for 30 minutes at 5°C to 10°C. The solid obtained was filtered under vacuum and washed with deionized water (2 x 20 mL). The wet solid was dried under vacuum at 35°C to 40°C for 14 hours to obtain the title compound.
Yield: 88.5%
¾ NMR (de-DMSO, 400 MHz): δ 3.92 (s, 3H), 6.48-6.51 (m, 1H), 7.30-7.32 (m, 1H), 7.64-7.65 (d, 1H), 8.10 (s, 1H), 8.44 (s, 1H), 8.52 (s, 1H).
Mass (m/z): 400.1 [m+2]+
Example 6: Preparation of 5-[(4-bromo-2-chlorophenyl)amino]-N-[2-(ethenyloxy)ethoxy]- 4-fluoro- 1 -methyl- lH-benzimidazole-6-carboxamide
N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (1.57 g) and
Hydroxybenzotriazole (1.25 g) were added to a solution of 5-[(4-Bromo-2- chlorophenyl)amino]-4-fluoro-l-methyl-lH-benzimidazole-6-carboxylic acid (2.0 g; obtained from Example 5) in dimethylformamide (20 mL) and the reaction mixture was stirred at 25°C to 30°C. Triethylamine (1.73 mL) was added to the reaction mixture slowly at 25°C to 30°C over a time period of 10 minutes. A solution of 0-[2-
(ethenyloxy)ethyl]hydroxylamine (0.97 g in dimethylformamide (2 mL)) was added to the reaction mixture and stirred at 25°C to 30°C for 24 hours. After completion of the reaction (monitored by TLC), deionized water (100 mL) was added and the reaction mixture was stirred for 1 hour at 20°C to 25°C to obtain a brown solid. The solid obtained was filtered under vacuum and washed with deionized water (2 x 20 mL). The wet material was dried under vacuum at 35°C to 40°C for 14 hours to obtain the title compound.
Yield: 70% Example 7: Preparation of 5-r(4-Bromo-2-chlorophenyl)aminol-4-fluoro-N-(2- hvdroxyethoxy)-l-methyl-lH-benzimidazole-6-carboxamide (Selumetinib)
Aqueous hydrochloric acid (IN, 1.2 mL hydrochloric acid in 12 mL deionized water) was added slowly to a solution of 5-[(4-Bromo-2-chlorophenyl)amino]-N-[2- (ethenyloxy)ethoxy]-4-fluoro-l -methyl- lH-benzimidazole-6-carboxamide (1.3 g; obtained from Example 6) in ethanol (30 mL) over a period of 10 minutes and the reaction mixture was stirred at 25 °C to 30°C for 24 hours. After completion of the reaction (monitored by TLC), ethanol was concentrated under vacuum. Ethyl acetate: tetrahydrofuran (3: 1, 45: 15 mL) was added and the organic layer was washed with saturated potassium carbonate solution (25 mL). The organic layer was separated and the aqueous layer was washed with ethyl acetate: tetrahydrofuran (45: 15 mL) solution. The organic layers were combined and dried over sodium sulphate and then concentrated under vacuum to obtain a crude compound as a brown solid (950 mg). The crude compound was further purified by column chromatography using 2% methanol/dichloromethane as an eluent to obtain the title compound.
Yield: 70%

Claims

Claims:
1. A compound of Formula 1,
Figure imgf000014_0001
Formula 1
wherein
R1 is independently selected from the group consisting of fluoro, chloro, bromo, phenylamino, or (4-bromophenyl)amino; and
R2 is independently selected from the group consisting of hydroxy, Ci-C6 alkoxy, 0-(2-vinyloxy-ethyl)-hydroxylamino, or 0-(hydroxyethyl)-hydroxylamino.
2. The compound according to claim 1, for use as an intermediate compound for the preparation of Selumetinib and Binimetinib.
3. A process for the preparation of compound of Formula 1 ,
Figure imgf000014_0002
Formula 1
wherein
R1 is independently selected from the group consisting of fluoro, chloro, bromo, phenylamino, (4-bromophenyl)amino, (4-bromo-2-chlorophenyl)amino, or (4- bromo-2-fluorophenyl)amino; and R2 is independently selected from the group consisting of hydroxy, C1-C6 alkoxy, 0-(2-vinyloxy-ethyl)-hydroxylamino, or O- (hydroxyethyl)-hydroxylamino,
comprising treating a compound of Formula 2 or a salt thereof,
Figure imgf000015_0001
Formula 2
wherein R1 and R2 are as defined above, with Ci-C6 dialkoxymethane in the presence of an acid.
4. The process according to claim 3 wherein the C1-C6 dialkoxymethane is selected from diethoxymethane or dimethoxymethane.
5. The process according to claim 3 wherein the acid is selected from the group consisting of an inorganic acid or an organic acid.
6. The process according to claim 5 wherein the inorganic acid is selected from the group consisting of hydrochloric acid and sulfuric acid.
7. The process according to claim 5 wherein the organic acid is selected from the group consisting of sulfonic acid derivatives or carboxylic acids.
8. The process according to claim 7 wherein the sulfonic acid derivatives are selected from the group consisting of methane sulfonic acid, / toluene sulfonic acid, and benzene sulfonic acid.
9. The process according to claim 7 wherein the carboxylic acid derivatives are selected from the group consisting of formic acid and acetic acid.
10. The process according to claim 3 wherein the compound of Formula 1 when R1 is not (4-bromo-2-chlorophenyl)amino and/or R2 is not O-(hydroxyethyl)- hydroxylamino can be further converted to Selumetinib.
11. The process according to claim 3 wherein the compound of Formula 1 when R1 is not (4-bromo-2-fluorophenyl)amino and/or R2 is not O-(hydroxyethyl)- hydroxylamino can be converted to Binimetinib.
PCT/IB2017/056133 2016-10-04 2017-10-04 Intermediates of mitogen-activated protein kinase kinase (map2k or mek) inhibitors and process for their preparation WO2018065924A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201611033910 2016-10-04
IN201611033910 2016-10-04

Publications (1)

Publication Number Publication Date
WO2018065924A1 true WO2018065924A1 (en) 2018-04-12

Family

ID=61830846

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/056133 WO2018065924A1 (en) 2016-10-04 2017-10-04 Intermediates of mitogen-activated protein kinase kinase (map2k or mek) inhibitors and process for their preparation

Country Status (1)

Country Link
WO (1) WO2018065924A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111087348A (en) * 2020-01-07 2020-05-01 长沙而道新能源科技有限公司 Preparation method of semetinib pharmaceutical intermediate
CN112679438A (en) * 2020-12-31 2021-04-20 武汉九州钰民医药科技有限公司 Process for the preparation of semetinib
CN112759552A (en) * 2020-12-31 2021-05-07 武汉九州钰民医药科技有限公司 Synthesis method of semetinib

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100130748A1 (en) * 2005-06-23 2010-05-27 Array Biopharma Inc. Snar process for preparing benzimidazole compounds
WO2010138377A1 (en) * 2009-05-28 2010-12-02 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
US20120277277A1 (en) * 2002-03-13 2012-11-01 Array Biopharma Inc. Methods of Treating a Hyperproliferative Disorder or Inhibiting Cell Growth in a Mammal

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120277277A1 (en) * 2002-03-13 2012-11-01 Array Biopharma Inc. Methods of Treating a Hyperproliferative Disorder or Inhibiting Cell Growth in a Mammal
US20100130748A1 (en) * 2005-06-23 2010-05-27 Array Biopharma Inc. Snar process for preparing benzimidazole compounds
WO2010138377A1 (en) * 2009-05-28 2010-12-02 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE PubChem [O] 26 March 2005 (2005-03-26), XP055498872, Database accession no. CID-10024 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111087348A (en) * 2020-01-07 2020-05-01 长沙而道新能源科技有限公司 Preparation method of semetinib pharmaceutical intermediate
CN112679438A (en) * 2020-12-31 2021-04-20 武汉九州钰民医药科技有限公司 Process for the preparation of semetinib
CN112759552A (en) * 2020-12-31 2021-05-07 武汉九州钰民医药科技有限公司 Synthesis method of semetinib

Similar Documents

Publication Publication Date Title
WO2018065924A1 (en) Intermediates of mitogen-activated protein kinase kinase (map2k or mek) inhibitors and process for their preparation
CN108368126B (en) Process for preparing 1, 3-benzodioxole heterocycles
CN114805314B (en) Synthesis method of Entecavir
WO2010142653A1 (en) A process for the preparation of febuxostat
EP2401253B1 (en) A process for the preparation of etoricoxib
CN112390725B (en) Preparation method of amide compound
KR20180116371A (en) Process for producing 4-alkoxy-3-hydroxypicolic acid
EP3583094B1 (en) Process for the preparation of 2-cyanoimidazole compounds
RU2631323C2 (en) Method for production of 4-benzyl-1-phenethyl-piperazin-2,6-dione, intermediate compound and method for its production
US9840622B2 (en) Azo dye composition and method for producing same
CA2110192A1 (en) Process for the preparation of phenylacetic acid derivatives
CN109715606B (en) Optimum method for producing pest control agent
US20040199002A1 (en) Process for producing(2-nitrophenyl)acetonitrile derivative and intermediate therefor
KR100915175B1 (en) Process for preparing imidapril
KR20200088570A (en) Process for Preparation of Fimasartan and Intermediate for Preparing the Same
BR112012029363B1 (en) PROCESS FOR PREPARING 1-ALKYL-3-DIFLUOROMETIL-5-HYDROXYPYROZOLS
AU2016345967A1 (en) Novel process for preparing thienopyrimidine compound and intermediates used therein
KR20110094751A (en) An improved process for preparing telmisartan
CN105384725A (en) Preparation method and applications of azimsulfuron key intermediate
KR101152607B1 (en) Process for preparing 6-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-3-pyridin-4-yl-pyrazolo[1,5-a]pyrimidine
CA3227445A1 (en) Production method for synthetic intermediate of monocyclic pyridine derivative
JP2536756B2 (en) 5-alkoxyanthranilic acid ester
JP5902671B2 (en) Process for producing benzylpyrazole derivative and production intermediate thereof
US20200262848A1 (en) Novel process for the preparation tavaborole and its intermediates
JP2001247549A (en) Method of producing 1-position substituted hydantoins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17857945

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17857945

Country of ref document: EP

Kind code of ref document: A1